NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE Amex: SNT) announced today that the Company will be presenting at the ROTH 23rd Annual OC Growth Stock Conference on Tuesday, March 15, 2011 at 4:30 p.m. Pacific Time (7:30 p.m. Eastern Time) at the Ritz-Carlton in Laguna Niguel, CA. President and Chief Executive Officer Leslie J. Browne, Ph.D., will be providing an update on its clinical plans as well as presenting a corporate overview and business update. The Company was granted Orphan Drug Status by the U.S. Food and Drug Administration (“FDA”) and submitted its first Investigational New Drug (“IND”) application for the Company’s lead drug candidate for multiple myeloma, SNS01-T, which upon approval from the FDA will allow the company to begin a Phase 1b/2a clinical study in multiple myeloma patients.
About Senesco Technologies, Inc.
Senesco Technologies is leveraging proprietary technology that regulates programmed cell death, or apoptosis. Accelerating apoptosis may have application in treating cancer, while delaying apoptosis may have application in certain inflammatory and ischemic diseases. The Company is preparing to initiate a human clinical study in multiple myeloma with its lead therapeutic candidate, SNS01-T. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology, and is entitled to earn research and development milestones and royalties should its gene-regulating platform technology be incorporated into its partners’ products.
Forward-Looking Statements
Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the ability of the Company to consummate additional financings; the development of the Company’s gene technology; the approval of the Company’s patent applications; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company's license agreements; the acceptance by the market of the Company’s products; the success and timing of the Company’s preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance; the Company’s ability to continue to comply with the continued listing standards of the NYSE/AMEX; and other factors expressed from time to time in the Company’s periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company’s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.